Content overview: “GLP-1 Drugs Like Ozempic Show Remarkable Potential in Reducing Heavy Alcohol Consumption, ”. A groundbreaking "gold standard" clinical trial has revealed that GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), can significantly reduce... marketwatch.comMay 1, 2026 • 1:57 PM1 views A groundbreaking "gold standard" clinical trial has revealed that GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), can significantly reduce heavy alcohol consumption in individuals with obesity and alcohol-use disorder (AUD). The study demonstrated that participants treated with semaglutide experienced a notable decrease in heavy drinking days compared to a placebo group.
This finding expands the therapeutic potential of these widely used metabolic drugs beyond weight management and diabetes. Researchers hypothesize that GLP-1s may influence the brain's reward pathways, dampening cravings and the rewarding effects of alcohol. While promising, further research is needed to confirm long-term efficacy, safety, and optimal use for AUD. The full version stays on the original page, which this listing opens directly.